Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas

Nuclear Medicine and Biology

Volumn 40, Issue 6, 2013, Pages 808-815

  Sasajima, Toshio ^a   Ono, Takahiro ^a   Shimada, Naoya ^a   Doi, Yoshihiro ^b   Oka, Shuntaro ^b   Kanagawa, Masaru ^b   Baden, Atsumi ^b   Mizoi, Kazuo ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nihon Medi Physics   (Japan)

Author keywords

Anti FACBC; Glioma; Methyl l methionine; MRI; Temozolomide

Indexed keywords

1 AMINO 3 FLUORO 1 CYCLOBUTANECARBOXYLIC ACID C 14; ALPHA METHYLMETHIONINE H 3; EVANS BLUE; FLUCICLOVINE F 18; GADOLINIUM PENTETATE MEGLUMINE; METHIONINE C 11; METHYLMETHIONINE C 11; METHYLMETHIONINE C 14; TEMOZOLOMIDE; THYMIDINE H 3; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; GLIOMA; GLIOMA CELL; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOACTIVITY; RAT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION;

EID: 84881022937     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.04.007     Document Type: Article

References (27)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Gilbert M.R., Loghin M. The treatment of malignant gliomas. Curr Treat Options Neurol 2005, 7:293-303.
3. Brandsma D., van den Bent M.J. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009, 22:633-638.
4. 11C-l-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008, 10:1-18.
5. 18F] 1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999, 40:331-338.
6. 18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 2011, 52:822-829.
7. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007, 48:56-63.
8. 14C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol 2012, 39:109-119.
9. Sasajima T., Miyagawa T., Oku T., Gelovani J.G., Finn R., Blasberg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging 2004, 31:1244-1256.
10. Nakagawa S., Deli M.A., Kawaguchi H., Shimizudani T., Shimono T., Kittel A., et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009, 54:253-263.
11. Mies G., Bodsch W., Paschen W., Hossmann K.A. Triple-tracer autoradiography of cerebral blood flow, glucose utilization, and protein synthesis in rat brain. J Cereb Blood Flow Metab 1986, 6:59-70.
12. Sasajima T., Mineura K., Kowada M., Hatazawa J., Miura S. Intracarotid recombinant human tumor necrosis factor-α reduces cerebral blood flow and methionine uptake in rat brain tumors. J Neurooncol 1997, 34:123-129.
13. Muskhelishvili L., Latendresse J.R., Kodell R.L., Henderson E.B. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67 (MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem 2003, 51:1681-1688.
14. 3H]methyl-l-methionine. J Nucl Med 2000, 41:1250-1255.
15. 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002, 29:176-182.
16. 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999, 22:210-214.
17. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61:1957-1963.
18. + -dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal. Am J Physiol Endocrinol Metab 2004, 287:E622-E629.
19. Laterra J., Keep R., Betz L.A., Goldstein G.W. Blood-brain barrier. In: Basic Neurochemistry. National Center for Biotechnology Information (NCBI) Accessed 27 Feb 2013. http://www.ncbi.nlm.nih.gov/books/NBK28180.
20. 18F]FACBC uptake in normal brain. J Nucl Med 2006, 47(Suppl):362P.
21. Miyagawa T., Oku T., Uehara H., Desai R., Beattie B., Tjuvajev J., et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998, 18:500-509.
22. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998, 50:1316-1322.
23. 11C]methionine and MRI. J Nucl Med 2006, 47(Suppl):79P.
24. Roessler K., Gatterbauer B., Becherer A., Paul M., Kletter K., Prayer D., et al. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 2007, 50:273-280.
25. 11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging 2010, 37:84-92.
26. 11C]-methionine positron emission tomography. Mol Imaging 2011, 10:453-459.
27. 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006, 33:516-524.